Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2019
Price : $35 *
At a glance
- Drugs Telisotuzumab vedotin (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors AbbVie
- 14 Oct 2019 Planned number of patients changed from 330 to 310.
- 14 Oct 2019 Planned End Date changed from 12 Oct 2023 to 15 May 2024.
- 18 Sep 2019 Planned number of patients changed from 310 to 330.